Cargando…
Determination of lower cut‐off levels of adalimumab associated with biochemical remission in Crohn's disease
BACKGROUND AND AIM: Adalimumab is administered and dosed using a standardized treatment regimen. Although therapeutic drug monitoring (TDM) may help optimize treatment efficacy, the lower cut‐off concentration of adalimumab needed to retain disease remission has not been established. This cross‐sect...
Autores principales: | Carlsen, Arne, Omdal, Roald, Karlsen, Lars, Kvaløy, Jan Terje, Aabakken, Lars, Steinsbø, Øyvind, Bolstad, Nils, Warren, David, Lundin, Knut Erik Aslaksen, Grimstad, Tore |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Wiley Publishing Asia Pty Ltd
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7273736/ https://www.ncbi.nlm.nih.gov/pubmed/32514446 http://dx.doi.org/10.1002/jgh3.12266 |
Ejemplares similares
-
Subtherapeutic concentrations of infliximab and adalimumab are associated with increased disease activity in Crohn’s disease
por: Carlsen, Arne, et al.
Publicado: (2018) -
Heat-shock protein 90α in plasma reflects severity of fatigue in patients with Crohn’s disease
por: Grimstad, Tore, et al.
Publicado: (2019) -
Histologic healing and factors associated with complete remission following conventional treatment in ulcerative colitis
por: Steinsbø, Øyvind, et al.
Publicado: (2022) -
Fatigue: a frequent and biologically based phenomenon in newly diagnosed celiac disease
por: Skjellerudsveen, Berit Mære, et al.
Publicado: (2022) -
Less, but not gone—gluten-free diet effects on fatigue in celiac disease: a prospective controlled study
por: Skjellerudsveen, Berit Mære, et al.
Publicado: (2023)